Intercept Pharmaceuticals Inc. shares ICPT, -39.73% More than 30% fell in pre-market trade on Monday, after the company said it received a full response letter from the U.S. Food and Drug Administration regarding its new request for drugs for treatment. for fibrosis caused by non-alcoholic steatohepatitis, or NASH. The letter …
Read More »
Text size Dirk Waem / Getty Images NASH was once the next big thing for big drug companies; a newly defined disorder that requires chronic treatment that affects millions of people in developed countries. Dozens of companies are developing drugs for the disease, which can cause life-threatening conditions like decompensated …
Read More »
Intercept Pharmaceuticals Inc. shares ICPT, -2.65% More than 30% fell in pre-market trade on Monday, after the company said it received a full response letter from the U.S. Food and Drug Administration regarding its new request for drugs for treatment. for fibrosis caused by non-alcoholic steatohepatitis, or NASH. The letter …
Read More »